Amylyx Pharmaceuticals Announces Positive Phase 3 LUCIDITY Results for Avexitide

What Happened

• Amylyx Pharmaceuticals (AMLX) filed an 8-K on August 18, 2026 reporting positive topline results from LUCIDITY, a 78‑participant, multicenter, randomized, double‑blind, placebo‑controlled Phase 3 trial of avexitide in post‑bariatric hypoglycemia (PBH) following Roux‑en‑Y gastric bypass. The trial met the FDA‑agreed primary endpoint: a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events versus placebo through Week 16 (p = 0.000003). All secondary endpoints were also met, showing consistent, statistically significant reductions in SMBG‑measured Level 2 events, CGM‑measured Level 2 events, and independently adjudicated Level 3 events.

Key Details

• Trial size and design: 78 adult participants randomized 3:2 to 90 mg avexitide subcutaneously once daily or placebo.
• Primary result: 55% reduction in composite Level 2+3 hypoglycemic events vs. placebo (p = 0.000003) through Week 16.
• Safety: Avexitide was generally well tolerated; most adverse events were mild–moderate. No serious adverse events were attributed to avexitide. Most common AEs: diarrhea, injection site erythema, and bruising. No mean weight changes observed during the 16‑week double‑blind period.
• Regulatory/timing: Amylyx plans to submit a New Drug Application (NDA) to the FDA by the end of 2026. Avexitide has prior FDA Breakthrough Therapy designation. The 32‑week open‑label extension and an expanded access program remain ongoing.

Why It Matters

• For investors, these robust Phase 3 topline results are a major clinical milestone: they materially advance avexitide toward an NDA submission and potential FDA approval for PBH, a condition with limited approved treatments. The highly significant p‑value and consistent secondary endpoint performance strengthen the clinical case. Safety findings reported here are consistent with prior PBH trials. Amylyx’s stated plan to file an NDA by year‑end 2026 and the drug’s Breakthrough Therapy status are key near‑term regulatory catalysts, though the company also notes standard forward‑looking risks and uncertainties in its filing.